Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis

NCT01262898 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

79

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastroparesis

Interventions

DRUG: GSK962040 (5 mg tablet)
DRUG: GSK962040 (25 mg tablet)
DRUG: GSK962040 (125 mg tablet)
DRUG: Placebo

Sponsor

GlaxoSmithKline